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Abstract
Background: Demyelination and axonal degeneration, hallmarks of multiple sclerosis (MS), are associated with the
central nervous system (CNS) inflammation facilitated by C-X-C motif chemokine 12 (CXCL12) chemokine. Both in
MS and in experimental autoimmune encephalomyelitis (EAE), the deleterious CNS inflammation has been associated
with upregulation of CXCL12 expression in the CNS. We investigated the expression dynamics of CXCL12 in the CNS
with progression of clinical EAE and following spontaneous recovery, with a focus on CXCL12 expression in
the hippocampal neurogenic dentate gyrus (DG) and in the corpus callosum (CC) of spontaneously recovered
mice, and its potential role in promoting the endogenous myelin/neuronal repair capacity.
Methods: CNS tissue sections from mice with different clinical EAE phases or following spontaneous recovery
and in vitro differentiated adult neural stem cell cultures were analyzed by immunofluorescent staining and
confocal imaging for detecting and enumerating neuronal progenitor cells (NPCs) and oligodendrocyte
precursor cells (OPCs) and for expression of CXCL12.
Results: Our expression dynamics analysis of CXCL12 in the CNS with EAE progression revealed elevated CXCL12
expression in the DG and CC, which persistently increases following spontaneous recovery even though CNS
inflammation has subsided. Correspondingly, the numbers of NPCs and OPCs in the DG and CC, respectively,
of EAE-recovered mice increased compared to that of naïve mice (NPCs, p < 0.0001; OPCs, p < 0.00001) or
mice with active disease (OPCs, p < 0.0005). Notably, about 30 % of the NPCs and unexpectedly also OPCs
(~50 %) express CXCL12, and their numbers in DG and CC, respectively, are higher in EAE-recovered mice
compared with naïve mice and also compared with mice with ongoing clinical EAE (CXCL12+ NPCs, p < 0.005;
CXCL12+ OPCs, p < 0.0005). Moreover, a significant proportion (>20 %) of the CXCL12+ NPCs and OPCs co-express the
CXCL12 receptor, CXCR4, and their numbers significantly increase with recovery from EAE not only relative to naïve
mice (p < 0.0002) but also to mice with ongoing EAE (p < 0.004).
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Conclusions: These data link CXCL12 expression in the DG and CC of EAE-recovering mice to the promotion
of neuro/oligodendrogenesis generating CXCR4+ CXCL12+ neuronal and oligodendrocyte progenitor cells endowed
with intrinsic neuro/oligondendroglial differentiation potential. These findings highlight the post-CNS-inflammation role
of CXCL12 in augmenting the endogenous myelin/neuronal repair capacity in MS-like disease, likely via CXCL12/CXCR4
autocrine signaling.
Keywords: Multiple sclerosis, Experimental autoimmune encephalomyelitis (EAE), CXCL12, Neuronal progenitor cells,
Oligodendrocyte precursor cells, Myelin and neuronal repair
Background
Demyelination and axonal degeneration, the hallmarks of
multiple sclerosis (MS), have long been associated with
the central nervous system (CNS) inflammation [1]. Che-
mokines are important mediators of the inflammatory re-
sponse, and the chemokine-guided influx of inflammatory
cells into the CNS is a major contributor to myelin dam-
age and axonal degeneration. The inflammation observed
in the CNS of MS patients and of mice with experimental
autoimmune encephalomyelitis (EAE) is associated with
increased expression of the C-X-C motif chemokine 12
(CXCL12) [2–5]. As a strong chemoattractant for T- and
B-lymphocytes and inflammatory monocytes, CXCL12 is
regarded as a mediator of pathogenic inflammation in the
CNS. Recently, however, the function of CXCL12 in the
CNS of mice with EAE, and apparently also of MS pa-
tients, was shown to be more complex; depending on its
interaction with receptors CXCR4 or CXCR7 and on its
spatial and temporal expression, CXCL12 may be anti-
inflammatory [4], immunomodulatory [6], and may also
promote remyelination [7–10].
CXCL12 is a key pleiotropic chemokine. In addition
to its essential function in regulating hematopoiesis and
in the patterning of the immune system, it plays an im-
portant role in the plasticity and patterning of the CNS
[7, 11, 12]. During embryonic development, CXCL12 is
crucial for neural stem cells (NSCs) proliferation, sur-
vival and migration, intercellular communication, and
neuronal axon guidance [7, 11, 13, 14]. CXCL12 and its
receptors, CXCR4 or CXCR7, are also expressed in the
adult brain [11, 15], where the CXCL12/CXCR4 axis
plays a central role in regulating the survival, prolifera-
tion, maturation, and migration of NSCs in response to
CNS insults, including neuroinflammation-associated
disorders, suggesting that CXCL12/CXCR4 axis is im-
portant also in adult neuro/oligodendrogenesis follow-
ing CNS damage [13, 16–20].
Although expression patterns of CXCR4 and its CXCL12
ligand have been extensively investigated during CNS
development and in healthy and injured adult CNS
[7, 10, 11, 21], few studies have analyzed functions of
CXCL12 in the context of CNS demyelinating diseases
such as EAE/MS [7, 8, 22]. In relapsing/remitting MS, the
most common form of the disease, relapse episodes are
associated with demyelination and neuronal damage.
Albeit limited, spontaneous remyelination may occur in
MS [23] and, more profoundly, in viral model of MS
[24]. Remyelination occurs via oligodendrocyte precur-
sor cells (OPCs), which are derived primarily from
NSCs that persist in the adult brain in neurogenic
niches lining the subventricular zone of the lateral ven-
tricles and the subgranular layer of the hippocampal
dentate gyrus (DG). The NSCs are self-renewing and
can differentiate to neuronal progenitor cells (NPCs)
and to OPCs [7, 11]. The OPCs migrate to demyeli-
nated areas in the CNS where they differentiate into
mature myelin-producing oligodendrocytes [7, 25].
It has been proposed that CXCL12 via its CXCR4 recep-
tor plays a role also in regulating the survival and migra-
tion of NSCs in response to CNS trauma, such as brain
tumors, ischemia, and neuroinflammation-associated dis-
orders [13, 16–20], and in regulating the migration and
survival of OPCs in vitro [26, 27]. In vivo, the role of
CXCL12 and its CXCR4 receptor in promoting the differ-
entiation of OPCs and their remyelination has been
demonstrated in mice following cuprizone-induced de-
myelination [8] and ischemia-induced demyelination [10].
Yet, the potential effect of CXCL12 on NPCs or OPCs
during the clinical course of EAE, a model for MS, and its
possible relevance to spontaneous recovery from the
disease is yet to be elucidated.
In this study, analysis of the expression dynamics of
CXCL12 in the CNS of mice during the progression
of clinical EAE and following spontaneous recovery
showed that CXCL12 expression, which increased with
disease progression, did not decline to basal levels in the
CNS of spontaneously recovered mice. In recovered mice,
CXCL12 levels remained significantly elevated relative to
those in naïve CNS, although CNS inflammation and
CXCL12-producing inflammatory cells had been abol-
ished during recovery. The post-inflammatory CXCL12
expression in the CNS of spontaneously recovered mice
was associated with a significant increase in numbers of
NPCs and OPCs at the DG and corpus callosum (CC),
respectively, that expressed the CXCL12. Notably, a sig-
nificant proportion of the NPCs and OPCs co-expressed
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CXCL12 and its receptor, CXCR4. The significant in-
crease in numbers of CXCL12+ CXCR4+ NPCs and
OPCs, which have an intrinsic potential to proceed to-
wards differentiation to mature neuronal cells or oligo-
dendrocytes, likely via autocrine signaling mechanisms,
links the post-inflammatory expression of CXCL12 with
post-CNS-inflammation elevation of endogenous mye-
lin/neuronal repair capacity associated with spontan-
eous recovery from clinical EAE.
Methods
Reagents and antibodies
The mouse PLP139-151 peptide was synthesized in the
laboratory of Prof. M. Fridkin (Department of Organic
Chemistry, Weizmann Institute of Science), using the
Fmoc technique with an automated peptide synthesizer
(AMS422; ABIMED, Langenfeld, Germany).
Antibodies used for immunostaining included the follow-
ing: mouse anti- CXCL12 (clone K15C kindly provided by
Prof. Tzvi Lapidot; Weizmann Institute, Israel); rabbit anti-
CD3 (NeoMarkers, Fremont, CA); rat anti-mouse MAC2
(Biolegend); monoclonal mouse anti-GFAP (Sigma); rabbit
anti-GFAP (Dako); rat anti-MBP (Chemicon); rabbit anti-
NF200 (Sigma); goat anti-DCX (Chemicon); monoclonal
mouse anti-β-Tubulin III (Chemicon); rabbit anti NG2
(Chemicon); and rat anti-CXCR4 (eBioscience).
The chemokine receptor antagonist, bicyclam AMD3100,
was purchased from Sigma-Aldrich (St. Louis, MO, USA).
Animals
C57Bl/6J and SJL/J mice were purchased from Harlan
(Jerusalem, Israel), and (C57Bl/6J × SJL/J) F1 mice were
bred and maintained at the Weizmann Institute Animal
Facility under specific pathogen-free conditions. All ani-
mal procedures and experimental protocols were ap-
proved by the IACUC of the Weizmann Institute (permit
number 02820711-3) and were performed in compliance
with its relevant guidelines and regulations.
Induction of EAE and tissue processing
For our experiments, PLP/EAE in (C57BL × SJL/J) F1
mice was found to be more suitable model than PLP/
EAE in SJL/J mice. In our animal facilities, the disease in
SJL/J mice was more severe (and with morbidity) than
the disease in the F1 mice. PLP/EAE in (C57BL × SJL/J)
F1 mice was with less morbidity and with more mice
that recover from the disease spontaneously, mice that
were necessary for the experiments in this study.
(C57BL × SJL/J) F1 mice (females, 7–8 weeks old) were
injected subcutaneously at one site in the flank with
200 μl of emulsion containing PLP139-151 (100 μg) in
CFA containing 300 μg mycobacterium tuberculosis
H37Ra (Difco). Mice received 300 ng pertussis toxin in
500 μl PBS in the tail vein immediately and 48 h after
immunization. Following the encephalitogenic challenge,
mice were observed and scored as previously described
[28]. For further tissue processing, mice were anesthe-
tized with a xylazine/ketamine mixure and perfused in-
tracardially with cold 4 % paraformaldehyde (PFA).
Spinal cords and brains were post-fixed in 2 % PFA and
cryoprotected in a 15 % sucrose solution. Free-floating
sections (16 μm thick for the spinal cord and 30 μm
thick for the brain were cut coronally with a sliding
microtome (Leica SM 2000r; Leica, Nussloch, Germany)
and stored at 4 °C prior to immunolabeling.
Immunolabeling and quantification
Immunocytochemistry
Coverslips were washed with PBS, fixed with 2 % PFA,
treated with a permeabilization/blocking solution
[(10 % FCS, 2 % bovine serum albumin, 1 % glycine,
and 0.1 % Triton X-100 (Sigma-Aldrich, Rehovot,
Israel)] and stained with either of the following anti-
bodies (diluted in the permeabilization/blocking solu-
tion): monoclonal anti-mouse GFAP (1:400); rabbit
anti-NG2 (1:200); rat anti-MBP (1:300); goat anti-DCX
(1:200); monoclonal anti-β-tubulin III (1:500); rabbit
anti-NF200 (1:500); and monoclonal anti-CXCL12
(1:84). Cover slips were exposed to primary antibodies
for 1 h in a humidified chamber at room temperature.
Secondary anti-IgG antibodies used included: Cy3-
conjugated goat anti-mouse, Cy3-conjugated goat
anti-rabbit, Alexa488-conjugated donkey anti-rabbit,
Cy2-conjugated donkey anti-rat, Rhodamine Red™-x-
conjugated donkey anti-goat, Cy3-conjugated goat
anti-mouse, Cy5-conjugated donkey anti-mouse, and
Cy5-conjugated donkey anti-rat. All secondary anti-
bodies were purchased from Jackson ImmunoResearch
Laboratories Inc. and used at a dilution of 1:250,
except for Rhodamine Red™-x-conjugated donkey anti-
goat (1:100). Cover slips were exposed to secondary
antibodies for 1 h in a humidified chamber at room
temperature. Following the immunostaining, cells
were counterstained with 4′,6′-diamidino-3-phenylin-
dole (DAPI) to visualize the nuclei. Control coverslips
(not treated with primary antibody) were used to dis-
tinguish specific staining from non-specific staining or
autofluorescent components.
Slides were examined using an LSM 510 laser scan-
ning confocal microscope (Carl Zeiss, Jena, Germany).
Digital images were acquired using the Zeiss LSM 510
software (magnifications ×10, ×25, ×40, or ×63). Images
were processed using Photoshop software.
Immunofluorescent staining of tissue sections
Free-floating sections of the spinal cord or brain were
washed twice in PBS followed by blocking in 3 % rabbit
or goat serum and 0.1 % Triton-X-100 in PBS for 1 h at
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RT. Samples were stained with the following antibodies
in 1 % of the appropriate serum and 0.1 % Triton-X-100
in PBS at 4 °C for overnight: monoclonal anti CXCL12
(1:84) with rabbit anti-GFAP (1:200), rabbit polyclonal
anti NG2 (1:200), or with goat anti DCX (1:200). In
some cases, samples were stained with rat anti MAC2
(1:200), rabbit anti CD3 (1:100), or with rat anti CXCR4
(1:200). For detection of primary antibodies, samples
were stained with either of the secondary antibodies de-
scribed above. Images were acquired as described above.
Quantification
Quantification of CXCL12 and the number of
MAC2+/CD3+, GFAP+, DCX+, and NG2+ alone or
with CXCL12 at the different stages of EAE was
performed on the same groups of animals. For ana-
lysis of the brain tissues, CD3+ and MAC2+ cells
were quantified in the forebrain and midbrain and
averaged; MAC2+ cells were also quantified in the
dentate gyrus. Astrocytes were scored in the den-
tate gyrus by counting GFAP+ and GFAP+/CXCL12+
cells. Neuronal progenitor cells were scored by counting
DCX+ cells in the subgranular zone (SGZ) of the dentate
gyrus as well as DCX+/CXCL12+ cells. Oligodendrocyte
progenitor cells were scored by counting NG2+ cells in
the corpus callosum as well as NG2+/CXCL12+ cells. All
cell lineages are expressed as mean number of cells per
square millimeter. For quantification, 5–6 coronal con-
secutive sections (at 300 μm intervals) per mouse brain
were stained, counted, and calculated for square milli-
meter. The nuclei of cells were visualized by DAPI
counterstaining.
For in vitro analysis, the percentage of antibody-labeled
cells was determined by evaluating 800–1000 cells in at
least six randomly chosen fields of view (under ×20 ob-
jective). All analyses were performed by an observer
blinded to identity of the examined slides.
Image analysis
Quantitative colocalization analysis has been extensively
used to reliably determine the colocalization of proteins.
The method used in this study has been previously de-
scribed [29]. The weighted colocalization coefficient
(WCC), which is the sum of intensities of colocalizing
pixels relative to the overall sum of pixel intensities
above the threshold (or background), was used to deter-
mine the relative levels of CXCL12 that colocalized with
NG2 immunoreactive cells. This was calculated using
the colocalization module according to Manders et al.
[30]. The advantage of a weighted colocalization coeffi-
cient is that differences in pixel intensity are taken into
account (i.e., not all pixels contribute equally to the final
colocalization coefficient value).
Adult neural stem cell culture
The neural stem cells were generated from the subven-
tricular zone (SVZ) of the lateral ventricle from brains of
C57Bl/6 mice (5–7 weeks old). Briefly, SVZ was isolated
following coronal sectioning and cut into 1 mm3 pieces.
The tissue was minced and incubated for digestion at
37 °C, 5 % CO2 for 45 min in 0.25 % Trypsin-EDTA
(Biological industries, Beit-Haemek, Israel). Following
centrifugation at 110g for 10 min at room temperature,
the tissue was further digested in Earle’s balanced salt
solution containing 0.94 mg/ml papain (Sigma-Aldrich,
Rehovot, Israel) and 0.01 % DNase (Sigma-Aldrich,
Rehovot, Israel) for 30 min at 37 °C, 5 % CO2. Then, the
tissue was mechanically dissociated by pipette trituration.
Single-cell suspension were plated (3500 cells/cm2) in
75 cm2 Falcon tissue culture flasks (BD Biosciences,
Franklin Lakes, NJ, USA), in Neurospheres medium
[Dulbecco’s modified Eagles’ medium (DMEM):F12
medium (Invitrogen Corp.) supplemented with B27 supple-
ment (Invitrogen Corp.), glucose, Hepes, bFGF (human
recombinant, 20 ng/ml) and EGF (mouse recombinant,
20 ng/ml); both from PeproTech, (Rocky hill, NJ, USA)].
Fresh media was added every 3–4 days to maintain the
cells as proliferating neurospheres, which were then pas-
saged every 4–6 days and re-plated as single cells.
The neurospheres were differentiated towards different
neural lineages by plating cells on Poly-D-lysine [PDL
(Sigma-Aldrich, Rehovot, Israel)], in growth factor-free
neurosphere medium containing 5 % serum (differentiation
medium). For immunocytochemistry, cells were plated on
coverslips pre-coated with PDL. In some differentiation
experiments, NSCs (2 × 104) were cultured in the presence
or absence of 10 ng/ml CXCL12 (PeproTech, Rocky hill,
NJ, USA) in differentiation medium. To monitor the effect
of the CXCR4 antagonist AMD3100 on differentiation of
NSCs, AMD3100 (100 ng/ml, Sigma-Aldrich, Rehovot,
Israel) was applied with or without CXCL12 (10 ng/ml) for
4 days in differentiation medium. AMD3100 was replaced
twice a day.
Densitometry and statistical analysis
ImageJ densitometry software (version 1.36, National Insti-
tutes of Health, Bethesda, MD, USA) was used for quantifi-
cation of CXCL12 intensity from images of brain sections.
Results are expressed as mean ± SEM. Statistical signifi-
cance was assessed with an unpaired two-tail Student’s
t test (Excel software). P < 0.05 was considered significant.
Results
CXCL12 expression is elevated in the CNS at EAE onset
and remains high following spontaneous recovery
Sites of inflammation in the CNS of mice with EAE are
associated with increased levels of CXCL12 [3, 11, 13]. Ac-
cordingly, strong immunofluorescent staining of CXCL12
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was detected in the posterior funiculus of the spinal cord,
expressed mainly by GFAP+ astrocytes (Additional file 1:
Figure S1a, b), and in the cortex (Additional file 1:
Figure S1c) of mice with EAE. Unexpectedly, however,
analysis of brains of mice at different stages of EAE
(onset, peak, and recovery, as depicted in Fig. 1a) revealed
that the level of CXCL12, which intensified during disease
progression, remained high in the brains of mice that
spontaneously recovered from clinical EAE (Fig. 1b, c;
about twofold higher vs. naïve mice, p < 10−9; 7–10 days
after mice were free of clinical manifestations) and
returned to its basal level within 20 days after clinical re-
covery (data not shown). Notably, the levels of CXCL12
remained relatively high despite a decline in CNS inflam-
mation (Fig. 2a, b; 5.3- and 3.9-fold decreases in MAC2+
and CD3+ cells, respectively, at recovery compared to
peak; p < 0.0001).
The relatively high levels of CXCL12 that were sustained
in the CNS after mice recovered, and CNS inflammation
was abolished, raised the intriguing possibility that CXCL12
may play a beneficial physiological post-inflammatory role.
This hypothesis was based on data indicating that CXCL12
promotes differentiation and survival of neurons [31] and
neuron migration during CNS development [11, 12, 14],
and on its effect on the differentiation/maturation of OPCs
in vitro [27] or in vivo [8, 22]. To further explore this post-
Fig. 1 Clinical course of PLP139-151-induced EAE in a representative experiment and sampling CXCL12 expression in the CNS at different phases
of EAE. a EAE was induced in (C57Bl/6J × SLJ/J) F1 mice (n = 20) by immunization with PLP139-151/CFA and scored for the clinical manifestations
as described in “Methods” section. The horizontal bars indicate phase of disease progression at which mice were sacrificed for immunohistopathology
analysis of the CNS. In the second remission phase (denoted by asterisk), only individual mice that spontaneously fully recovered from EAE
(with a score =0 for 7–10 days) were used for immunohistopathology analysis of the CNS. These mice are referred to as EAE-recovered mice.
In this representative experiment, three mice fully recovered from clinical EAE on the days denoted by ŧ. Inset represents the clinical follow-up
of an individual mouse that spontaneously recovered from clinical EAE on day 48 and sacrificed for immunohistopathology analysis on day 60
post-immunization. b Quantification of CXCL12 immunofluorescence intensity in consecutive tissue sections taken from the forebrain, midbrain, and
hindbrain from naïve or mice at onset, peak of disease, or following spontaneous recovery (*p < 10−11, **p < 10−9). c Immunostaining for CXCL12 (red)
in the striatum (St) and the dorsal third ventricle (D3V). Data in b are from nine consecutive sections from each mouse, n = 3 mice/group. Error bars
represent mean ± SEM. All sections were counterstained with DAPI (blue) to visualize cell nuclei. Scale bar: 50 μm
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Fig. 2 (See legend on next page.)
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inflammatory function, we evaluated CXCL12 expression
during disease progression and following recovery in the
CC, and in the DG of the hippocampus as a known neuro-
genic niche. We observed similar dynamic expression pat-
terns of CXCL12 in the CC and DG, at different stages of
EAE and following recovery. There was a 2.2-fold increase
in expression level of CXCL12 in the CC at the peak of dis-
ease compared to its expression in naïve mice (Fig. 2c, d).
Following recovery, the expression of CXCL12 decreased
only slightly to 62.8 % of its level at the peak of the disease
and remained 1.38-fold higher than naïve levels (p < 0.001;
Fig. 2d). Similarly, the level of CXCL12 in the DG increased
with disease progression to about 2.5-fold of its basal level
in DG of naïve mice at the peak of the disease; after spon-
taneous recovery, CXCL12 expression declined to 53.4 %
of its level at the peak of the disease (p < 0.002 Figs. 2e, f)
and remained 1.35-fold higher than naïve levels (p = 0.039;
Fig. 2f). Thus, the CXCL12 levels remained elevated in CC
and DG even after recovery when the numbers of infiltrat-
ing CD3+ T cells (data not shown) and MAC2+ inflamma-
tory cells in DG were dramatically reduced (Fig. 2g, h). The
persistence of CXCL12 in the DG after clinical and patho-
logical recovery was observed in all mice tested, suggesting
that CXCL12 may have a physiological post-inflammatory
role, possibly in supporting neural repair.
We next sought to determine the source of the high
levels of CXCL12 in the CNS of EAE-recovered mice,
where only few inflammatory infiltrating cells remained
after the CNS inflammation subsided. Astrocytes are be-
lieved to be the major source of CXCL12 in the CNS of
MS patients [3] as well as in CNS of mice with cuprizone-
induced demyelination [8]. To examine whether astrocytes
were the source of CXCL12 present in the DG of EAE-
recovered mice, we determined the number of astrocytes
(GFAP+) as well as astrocytes expressing CXCL12 in the
DG of mice during EAE progression and recovery. As
shown in Fig. 2i, j, the numbers of GFAP+ CXCL12+ astro-
cytes were dramatically increased with disease progression
both in the DG hilus and SGZ. However, by 7–10 days
after clinical recovery, the numbers of GFAP+ CXCL12+
astrocytes declined almost to basal levels, whereas levels
of CXCL12 were sustained (Figs. 2e, f ). Thus, the
astrocytes are not likely to be the major source of CXCL12
in the DG of EAE-recovered mice.
It should be noted that the immunostaining analysis
of the DG and CC in mice that had not recovered
spontaneously from EAE (non-recovered) (scarified
for the analysis at the end point of the experiment on
day 65 post-immunization, Fig. 1a) showed staining inten-
sity for CXCL12, macrophages, and GFAP+ astrocytes
that was higher than that in spontaneously recovered
mice, albeit lower than that in mice at the peak of the
disease. (Additional file 2: Figure S2).
Numbers of DCX+ and DCX+ CXCL12+ NPCs increase with
spontaneous recovery
Despite the remarkably high levels of CXCL12 in the
spinal cord (Additional file 1: Figure S1a, b), we did not
detect CXCL12 expression in the relatively few NPCs
found in the spinal cord of mice with EAE (data not
shown). In contrast, a significant number of CXCL12-
immunoreactive NPCs (DCX+ CXCL12+) were detected
at the SGZ of the DG of mice during progression of
EAE and, notably, also following recovery (Fig. 3a, c). In
the immunostained sections from non-recovered mice (on
day 65 post-immunization) DCX+ NPCs co-expressing
CXCL12 were also noted, and the immunofluores-
cence intensity of DCX/CXCL12 co-staining was sig-
nificantly lower than that of immunostained sections
from recovered mice and was more comparable to
immunostained sections of mice at the peak of the
disease (Additional file 2: Figure S2e). The colocaliza-
tion of CXCL12 with DCX immunostaining (Fig. 3b),
which strongly suggests in situ expression of CXCL12
by the NPCs in the DG of mice with EAE, is in line
with previous reports of NPCs expressing CXCL12+
[4, 32, 33]. Quantitative analysis of the hippocampal
CXCL12 immunoreactive NPCs showed an approximately
fivefold increase in DCX+ CXCL12+ NPCs at the peak of
the disease compared to naïve mice (p < 3.3 × 10−7)
(Fig. 3c). The total number of NPCs (DCX+) in the DG
was also increased during EAE progression (approxi-
mately threefold; p < 7.4 × 10−5), albeit to a lesser extent
than DCX+ CXCL12+ NPCs, compared to naïve mice
(See figure on previous page.)
Fig. 2 Expression of CXCL12 in the CNS of mice during progression of clinical EAE and following spontaneous recovery. a, b Immunostaining for
MAC2 (green) in brain sections from the D3V and the quantification of activated macrophages/microglia (MAC2+) and infiltrating lymphocytes
(CD3+) in brain tissue sections from naïve mice or mice at onset, peak, or following recovery (*p < 0.0001; CD3 representative immunostaining
image not shown). c, d Immunostaining for CXCL12 (red) in brain sections from CC (central/caudal regions, denoted by dashed lines), and
respective quantification of CXCL12 intensity (*p = 6.5 × 10−5, **p = 0.001). e, f Immunostaining for CXCL12 (red) in brain sections from the DG,
and the respective quantification of CXCL12 intensity in brain sections from DG (*p = 0.004, **p = 0.039). g, h Immunostaining for MAC2 (red) in
the DG and the respective quantification of activated macrophages/microglia (MAC2+) (*p = 0.0003, **p = 0.006). i, j Co-immunostaining for GFAP
(green) and CXCL12 (red) in brain sections from the DG, i and the respective quantification of astrocytes (GFAP+) and astrocytes co-expressing
CXCL12 (GFAP+ CXCL12+) in DG (*p≤ 0.0002, **p≤ 0.0001). Data in b and d are from nine consecutive sections from each mouse, n = 3 mice/
group. Data in f, h, and j are from five consecutive sections from each mouse; n = 4 mice/group. Error bars represent mean ± SEM. All sections
were counterstained with DAPI (blue) to visualize cell nuclei. Scale bars: a, c, e, g, and i 50 μm
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(Fig. 3c). Remarkably, 7–10 days after the recovery from
clinical symptoms of EAE, the number of the DCX+
CXCL12+ NPCs was increased even further in the SGZ of
the DG (~1.3-fold above levels at peak of disease, p < 0.005;
and ~6.4-fold above naïve mice, p < 3.3 × 10−7) (Fig. 3c),
even though inflammation in the DG was minimal
(Figs. 2g, h). These results suggest a potential involvement
of CXCL12 in regulation of neuronal progenitor cell
replenishment in the brain, both during the EAE-incurred
CNS inflammation/damage, and even more so at the
recovery stage, when inflammation is diminished.
NG2+ and NG2+ CXCL12+ OPCs are significantly elevated
in the CNS of EAE-recovered mice
Consistent with previous studies [8, 34], we observed a
dramatic increase in numbers of NG2+ OPCs in the
spinal cord and in the CC (Figs. 4 and 5) of mice with
EAE. Quantitative analysis showed a remarkable increase
(by 11-fold; p ≤ 10−7) in the number of NG2+ OPCs in
the spinal cords of mice with clinical EAE compared to
naïve mice (Fig. 4a, b); of these, 61 % co-expressed
CXCL12 (Fig. 4b). Unlike NPCs and mature neuronal
cells that were shown in prior studies to express
CXCL12 [4, 32, 33], the expression of CXCL12 by OPCs
or oligodendrocytes had not been reported. To verify
that the co-immunostaining of CXCL12 with NG2+ cells
reflects the expression of CXCL12 by the OPCs rather
than a result of their binding CXCL12 secreted by other
cells such as activated microglial cells or astrocytes, we
carried out a colocalization analysis at high magnifica-
tion on sections of spinal cords from mice with EAE that
were co-stained for NG2, CXCL12, and DAPI. Figure 4c
shows a spinal cord section from mouse with EAE that
includes two adjacent NG2+ cells: one is negative and
the other one is immunoreactive for CXCL12. The cell
marked 2 in Fig. 4c was double-labeled for NG2 and
CXCL12; whereas the cell marked 1 was immunoreactive
for NG2 but negative for CXCL12 in four consecutive
confocal slices (Fig. 4d). The microscopic observations
were confirmed by evaluating the weighted colocalization
coefficients (WCC; see “Methods” section), which mea-
sured the pixel overlap between NG2 and CXCL12.
Quantitative analysis of the mean WCCs in the spinal
cord sections from mice with EAE indicated values of
Fig. 3 The numbers of NPCs and of CXCL12+ NPCs increase in DG of mice with the onset and the progression of clinical EAE and remain
relatively high following spontaneous recovery. a Representative images of the DG of mice with EAE clinical episodes or following spontaneous
recovery; sections were co-immunostained for DCX (green) and CXCL12 (red). b Orthogonal view of three-dimensional analysis showing NPC (DCX+,
green) expressing CXCL12 (red). The middle image is a higher magnification of boxed area in the left image taken from DG of EAE-recovered mouse.
Colocalization of DCX (green) and CXCL12 (red) was confirmed by optical dissection and orthogonal reconstruction of the confocal image (right image).
c Quantitative analysis of the NPCs (DCX+) and NPCs co-expressing CXCL12 (DCX+ CXCL12+) in SGZ of the DG of mice with EAE clinical episodes or
spontaneously recovered mice (*p < 7.4 × 10−5 and **p < 3.3 × 10−7, compared to naïve; ***p < 0.005, recovered compared to peak). Data are from five
consecutive sections from each mouse, n = 3 mice/group. Data are the mean ± SEM from two independent experiments. Nuclei were visualized by
DAPI counterstaining (blue). Scale bars: a, 50 μm; left image in b, 20 μm; boxed area in b, 5 μm
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Fig. 4 Numbers of CXCL12+ OPCs are elevated in the spinal cord of mice as EAE progresses and are further increased following spontaneous
recovery from the disease. a Representative images of the spinal cord tissue sections from naïve healthy mice and from mice with clinical EAE
(at the peak) co-immunostained for OPCs (NG2+, green) and CXCL12 (red). b Quantitative analysis of OPCs (NG2+) co-expressing CXCL12 (NG2+
CXCL12+) in the spinal cord of mice with EAE compared to naïve mice (*p < 10−7: data are from five consecutive sections per mouse, n = 3 mice/
group). c–e NG2+ OPCs and CXCL12 colocalize in the spinal cord sections of mice with EAE. c Confocal image of two OPCs (NG2+, green): one is
CXCL12 positive (red) and the other is CXCL12 negative, in a spinal cord section (L4) from a mouse with clinical EAE. d The left image is a higher
magnification of the boxed area in c. The right panel represents colocalization analysis of serial levels (each 0.5 μm). Numbers in the table represent
weighted colocalization coefficient (WCC) values of NG2+ cell that do not express CXCL12 (marked 1) compared to NG2+ cell that co-express
CXCL12 (marked 2). WCC values were measured with Zeiss LSM image examiner software. In the table, values for CXCL12 (red) denote the
colocalization coefficient from the red channel colocalized with the green channel, and the values for NG2 (green) denote the colocalization
coefficient from the green channel colocalized with the red channel for OPCs marked 1 and 2. e Quantitative analysis of the mean WCC values of
NG2+ OPCs co-expressing CXCL12 in mice with EAE compared to naïve mice (*p < 0.001, **p = 0.002). Data are from five consecutive sections from
each mouse, n = 3 mice/group. Error bars represent mean ± SEM from two independent experiments. Nuclei were visualized by DAPI staining (blue).
Scale bars: a 20 μm; c, d 10 μm. Arrowheads indicate OPCs (NG2+) that co-express CXCL12
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0.360 ± 0.007 and 0.31 ± 0.13 for NG2 and CXCL12, re-
spectively, compared to 0.014 ± 0.012 and 0.003 ± 0.004 in
the spinal cord sections from naïve healthy mice (Fig. 4e),
further indicating that the OPCs in the spinal cord of mice
with EAE express CXCL12.
The numbers of OPCs and of CXCL12-expressing
OPCs (NG2+ CXCL12+) in the CC were also increased
with the progression of the disease and further increased
following clinical recovery (Fig. 5). Figure 5a shows rep-
resentative images of CC from mice at different stages of
EAE co-immunostained for CXCL12, NG2, and DAPI.
In the immunostained sections from non-recovered mice
(on day 65 post-immunization) NG2+ OPCs co-expressing
CXCL12 were also noted, and the immunofluorescence
intensity of NG2/CXCL12 co-staining was significantly
lower than that of immunostained sections from recov-
ered mice and more comparable to immunostained sec-
tions of mice at the peak of the disease (Additional file 2:
Figure S2f). The orthogonal view (Fig. 5b) showing colo-
calization of NG2+ and CXCL12+ suggests the presence of
OPCs expressing CXCL12 also in the CC. Quantitative
analysis of NG2+ and NG2+ CXCL12+ OPCs in the CC
showed their significant increase at EAE onset and at dis-
ease peak compared to naïve mice (Fig. 5c). At the peak of
the disease, the numbers of NG2+ and NG2+ CXCL12+
cells expanded by 4.3- (p < 10−5) and 6.7- (p < 3 × 10−4)
fold, respectively, compared to naïve mice. Interestingly,
the numbers of NG2+ and NG2+ CXCL12+ OPCs contin-
ued to expand by 5.9- (p < 10−5) and to 12.7- (p < 3 × 10−4)
fold, respectively, in the CC of mice that recovered from
clinical EAE compared to naïve mice. These results
strongly suggest the involvement of CXCL12 also in the
regulation of OPCs both in the CC and spinal cord.
Expression of CXCL12 by in vitro differentiating OPCs and
NPCs
Astrocytes are a known source of CXCL12 in the CNS
[2, 3, 35]. To further determine whether cells of the
other neural lineages, particularly OPCs, also produce
CXCL12, we analyzed neural progenitor cells of in vitro
differentiated adult NSCs (aNSCs) (dissociated neuro-
spheres) (Additional file 3: Figure S3). Cultures from
Fig. 5 Numbers of CXCL12+ OPCs are elevated in the CC of mice with onset and the progression of clinical EAE and further increase following
spontaneous recovery from the disease. a Representative images of the CC of mice with EAE clinical episodes or following spontaneous
recovery; sections were co-immunostained for OPCs (NG2+, green) and CXCL12 (red). b Orthogonal view of an OPC (NG2+, green) in the CC of
EAE-recovered mouse that express CXCL12 (red). The middle image is a higher magnification of the boxed area in the left image. Colocalization of
NG2 (green) and CXCL12 (red) was confirmed by optical dissection and orthogonal reconstruction of the confocal image (right image). c Quantitative
analysis of the OPCs (NG2+) and OPCs that co-express CXCL12 (NG2+CXCL12+) in the CC of mice with EAE clinical episodes or following spontaneous
recovery (*p < 0.00001 and **p < 0.0003 compared to naive; ***p < 0.0005, recovered compared to peak, n = 4 mice/group). Data are from five
consecutive sections from each mouse. Data represent mean ± SEM from three independent experiments. Nuclei were visualized by DAPI counterstaining
(blue). Scale bar: a 50 μm; left image in b, 50 μm; boxed area in b, 5 μm. Arrowheads indicate OPCs (NG2+) co-expressing CXCL12
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different days of differentiation were extensively washed
and subjected to immunofluorescent staining for CXCL12
and markers of the different neural lineage progenitor
cells. As was observed previously (reviewed in [11]), the
in vitro differentiated astrocytes (GFAP+) expressed high
levels of CXCL12 (data not shown). The DCX+ neuronal
progenitor cells also co-expressed CXCL12 (Fig. 6a, upper
panel), in line with the studies of Tran et al. [32]. Import-
antly, although not previously observed, a significant pro-
portion of NG2+ OPCs co-expressed CXCL12 (Fig. 6a,
lower panel). A confocal reconstruction demonstrated that
CXCL12 was expressed by aNSCs that differentiated to
NG2+ OPCs, as CXCL12 staining could be detected in the
NG2+ cell body as well as along its processes (Fig. 6b) and
the WCC for this cell demonstrated overlapping pixels
between NG2 and CXCL12.
CXCL12 promotes differentiation of NPCs and OPC
in vitro
Neurospheres were differentiated in the absence or pres-
ence of exogenous CXCL12 (5, 10, or 20 ng/ml) in dif-
ferentiation medium. The effects of 10 and 20 ng/ml
Fig. 6 Expression of CXCL12 by NPCs and OPCs differentiated from aNSCs in vitro. a Representative images of differentiating aNSCs co-stained
for DCX (red) and CXCL12 (green) (upper panel) or for NG2 (green) and CXCL12 (red) (lower panel) at the indicated time points of differentiation.
b Orthogonal view from confocal z-series of OPC co-expressing CXCL12 (indicated with arrow in left image) presented as viewed in x-z (upper)
and y-z (right) planes (right image). The WCC values presented in the table demonstrate the colocalization of CXCL12 with NG2. Images shown are
representative of three independent experiments with similar results. Nuclei were counterstained with DAPI (blue). Scale bars: a 50 μm; b 20 μm
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recombinant CXCL12 on the in vitro differentiation and
maturation of aNSCs were higher than that of 5 ng/ml;
effects of 10 and 20 ng/ml CXCL12 were quite compar-
able, with 10 ng/ml being somewhat more optimal (sum-
marized in Additional file 4: Figure S4). Accordingly,
only the effects of 10 ng/ml recombinant CXCL12 on
differentiation and maturation of aNSCs (representative
images and quantitation) are presented in Fig. 7. Ex-
ogenous CXCL12 (10 ng/ml) significantly enhanced the
differentiation of aNSCs into NPCs (DCX+, Fig. 7a, b)
and OPCs (NG2+, Fig. 7a, c). Enhanced differentiation
was evident after a 4-day incubation in the presence of
CXCL12 and was more pronounced after 8 days, with 2-
and 1.5-fold increase in numbers of DCX+ and NG2+
cells, respectively (Fig. 7b, c). CXCL12 also promoted
the maturation of neuronal cells and oligodendrocytes,
as shown by immunostaining for β-tubulin III and mye-
lin basic protein (MBP), markers of mature neuronal
cells and oligodendrocytes, respectively (Fig. 7d–f ). Quan-
titative analysis showed that maturation of neuronal cells
(Fig. 7e) and oligodendrocytes (Fig. 7f) was significantly
enhanced. Higher (20 ng/ml) and to a lesser extent also
the lower (5 ng/ml) concentrations of CXCL12 had a simi-
lar effect (Additional file 4: Figure S4).
To further validate that CXCL12 promotes differenti-
ation/maturation of NPCs and OPCs, the CXCR4 antag-
onist, AMD3100, was added to aNSCs cultured in
differentiation medium in the absence or presence of
CXCL12. After 5 days, AMD3100 strongly inhibited the
differentiation of neuronal (DCX+) and oligodendrocyte
(NG2+) progenitor cells (Fig. 7g, top panel) and of their
maturation to neurons (β-tubulin III+) and oligodendro-
cytes (MBP+) (Fig. 7g, bottom panel). Quantitative analysis
confirmed the significance of the effect of AMD3100
(Fig. 7h, i). Notably, the presence of AMD3100, in the ab-
sence of exogenous CXCL12, also inhibited differentiation
and maturation of neuronal and oligodendrocyte progeni-
tors (Fig. 7a, b), compared to control differentiation cul-
tures (without AMD3100 or CXCL12). These results are
in line with previous study that showed inhibition of
CXCL12 activity by AMD3100 in vitro [36]. AMD3100
did not alter cell viability as confirmed by staining with
Hoescht 33342 and propidium iodide (data not shown).
The data obtained from this extensive in vitro analysis
suggest the role of CXCL12 in directing the differenti-
ation/maturation of neural progenitor cells in the CNS.
Our results are consistent with those of previous studies
showing that CXCL12 promotes, via CXCR4, the differen-
tiation or maturation of OPCs or NPCs in vitro [27] and
in vivo [8, 16].
CXCR4 and CXCL12 are co-expressed by NPCs and OPCs
CXCR4 is expressed by mature neuronal cells [37, 38],
NPCs [32], and OPCs [8, 26, 27, 39]; therefore, our finding
that CXCL12 is expressed by NPCs and by OPCs suggests
the intriguing possibility that neural progenitor cells may
in fact express both the CXCR4 receptor and its CXCL12
ligand. To confirm co-expression of CXCR4 and CXCL12
by NPCs and particularly by the OPCs, in vitro differenti-
ated cultures of aNSCs were co-stained for DCX/CXCR4/
CXCL12 or for NG2/CXCR4/CXCL12. As shown in Fig. 8,
a significant proportion of NPCs (Fig. 8a) and OPCs
(Fig. 8b) in these cultures co-expressed CXCR4 and
CXCL12. The frequencies of DCX+ CXCR4+ CXCL12+
among DCX+ NPCs and of NG2+ CXCR4+ CXCL12+
among NG2+ OPCs in the dense differentiation cultures
were relatively high (>50 %, data not shown). The finding
that NPCs and OPCs co-express the CXCR4 receptor
and its CXCL12 ligand suggested that differentiation/
maturation of these neural cells may occur via auto-
crine signaling mechanism [40, 41]. It was, therefore,
of high significance to examine whether neural pro-
genitor cells co-expressing CXCR4 and CXCL12 could
be detected also in the CNS. This analysis was carried
out in the CNS of mice with ongoing EAE or following
spontaneous recovery as more CXCL12+ NPCs and
CXCL12+ OPCs were detected in the CNS of these mice
compared to naïve mice (Figs. 3, 4, and 5). Figure 9a, c
shows representative images of a DCX+ NPC and an NG2+
OPC from EAE-recovered DG and CC, respectively, which
co-express CXCR4 and CXCL12. Quantitative analysis re-
vealed that the frequency of NPCs that co-express CXCR4
and CXCL12 among DCX+ CXCR4+ NPCs, and of OPCs
that co-express CXCR4 and CXCL12, among NG2+
CXCR4+ OPCs, were over 20 % in EAE-recovered mice
(Fig. 9b, d). Strikingly, a fraction of the DCX+ CXCR4+
NPCs and NG2+ CXCR4+ OPCs in naïve mice also co-
expressed CXCL12 (Fig. 9b, d).
In mice developing EAE, the proportion of DCX+
NPCs that co-expressed CXCR4 and CXCL12 (out of
DCX+ CXCR4+ NPCs in DG) increased significantly at
EAE onset to 11.59 ± 0.90 % (p = 0.01), and to 18.0 ±
1.0 % (p < 4 × 10−5) at the peak of disease, compared to
8.37 ± 1.80 % in naïve mice) (Fig. 9b). Moreover, follow-
ing clinical recovery from the disease, the proportion of
DCX+ CXCR4+ CXCL12+ NPCs further increased to
23.00 ± 2.13 % (~2.7-fold increase compared to naïve mice,
p < 4 × 10−5 and 1.98-fold compared to mice with ongoing
EAE, p = 6.5 × 10−5). In parallel, the frequency of NG2+
CXCR4+ CXCL12+ OPCs among the NG2+ CXCR4+
OPCs in the CC significantly increased to 20.0 ± 3.7 % at
EAE onset and to 23.7 ± 4.3 % at the peak of the disease,
compared to 13.31 ± 3.05 % in naïve CC (p = 0.01 and p =
0.003, respectively) (Fig. 9d). Furthermore, as shown in
Fig. 9d, the percentage of NG2+ CXCR4+ CXCL12+ OPCs
among the NG2+ CXCR4+ OPCs in the CC further in-
creased following clinical recovery to 28.80 ± 4.12 %, 2.16-
fold over naïve mice (p = 0.0002) and 1.43-fold over mice
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Fig. 7 (See legend on next page.)
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with ongoing EAE (p = 0.004). Hence, the proportion of
OPCs and NPCs in the CNS that co-expressed CXCR4
and CXCL12 increased as disease progressed and were fur-
ther elevated during recovery, even though CNS inflam-
mation has subsided. These findings further suggest the
involvement of CXCL12 in the endogenous myelin/neuronal
repair of the EAE-associated CNS damage by increasing
endogenous neuro/oligodendrogenesis and possibly also
the differentiation of NPCs and OPCs.
These increased numbers of CXCR4+ CXCL12+ neural
progenitor cells following recovery are of high signifi-
cance as a self-sufficient myelin/neural repair mechan-
ism (autocrine signaling) in the absence of CXCL12 after
the inflammatory cells diminished.
Discussion
The data presented in this study highlight the post-
inflammation role of CXCL12 in the context of en-
dogenous myelin/neuronal repair associated with the
spontaneous recovery from chronic clinical EAE. The
association of CXCL12 with a potential repair of EAE-
associated CNS tissue damage was initially suggested by
the unexpected but consistent detection of about twofold
increase in the expression of CXCL12 in the CNS of mice
that had spontaneously recovered from clinical EAE (com-
pared to naïve mice). We observed a relatively high ex-
pression of CXCL12 in the CC and in the neurogenic DG
of recovered mice up to 20 days after these mice were free
of clinical symptoms and their CNS inflammation had re-
solved. Post-inflammatory expression of CXCL12 was as-
sociated with an increase in numbers of CXCL12+ NG2+
OPCs and CXCL12+ DCX+ NPCs in the CC and DG,
respectively, of EAE-recovered mice not only compared to
naïve mice but also relative to EAE-affected mice at the
peak of the disease. These findings suggest the involve-
ment of CXCL12 in the endogenous myelin/neuronal
repair of the EAE-associated CNS damage is by increasing
endogenous neuro/oligodendrogenesis and possibly also
the differentiation of NPCs and OPCs. Prior in vitro stud-
ies [13, 42] and previous reports of the various functions
of CXCL12 during CNS development and following
injuries to the adult CNS, including demyelination
models, suggest the effect of CXCL12 on the proliferation
of neural progenitor cells [8, 10, 27, 43].
Strikingly, in the context of the beneficial post-
inflammatory role of CXCL12, we found that in mice with
EAE, a significant proportion of neural progenitor cells
co-express both CXCL12 and its CXCR4 receptor (Fig. 9).
Moreover, the proportions of these CXCL12+ CXCR4+
DCX+ NPCs and CXCL12+ CXCR4+ NG2+ OPCs, which
increased with disease progression further increased in re-
covered mice (2.12- and 2.75-fold, respectively, compared
to naïve mice; p ≤ 0.0002). These findings are consistent
with potential endogenous neuro/oligodendrogenesis and
neural differentiation that can contribute to myelin/neural
repair via autocrine signaling mechanisms, independently
of inflammation-induced CXCL12-producing cells (acti-
vated microglia/macrophages and astrocytes) which are
cleared from the CNS during spontaneous recovery from
clinical EAE.
The expression patterns and potential functions of
CXCR4 and its ligand CXCL12 have been widely investi-
gated during CNS development and in healthy or injured
adult CNS [7, 10, 11, 21, 44]. However, few studies have
analyzed the potential function of CXCL12 in the context
of myelin or neuronal repair in CNS inflammatory and
demyelinating diseases, such as EAE/MS [7, 8, 22, 25].
Our analysis of the expression dynamics of CXCL12 with
progression of EAE and following recovery consistently
indicate that CXCL12 expression is greater in the DG
and CC of mice which spontaneously recovered from
severe clinical EAE than in naïve mice. This was somewhat
surprising since the activated macrophages/microglial cells
and astrocytes, which were reported to be as the major
source of CXCL12 in the inflamed CNS of MS pa-
tients [3, 11, 45] and in the cuprizone-induced model of
demyelination [8, 9, 46] are abolished during the EAE re-
covery phase. Such an observation, therefore, raised the
question not only of the potential function for elevated
levels of CXCL12 in the DG and CC of EAE-recovered
mice but also of the origin of such elevated levels of
CXCL12 at the DG and the CC of EAE-recovered mice.
(See figure on previous page.)
Fig. 7 CXCL12 promotes and a CXCR4 antagonist inhibits differentiation and maturation of aNSCs. a Representative images of immunofluorescent
staining for NPCs (DCX+, red) and OPCs (NG2+, green) in cultures of aNSCs undergoing differentiation in the absence or presence of CXCL12 (10 ng/ml).
b Quantitative analysis of NPCs (DCX+). c Quantitative analysis of OPCs (NG2+). d Representative images of immunofluorescent staining for maturing
neurons (βΙΙΙ-tubulin+, green) or oligodendrocytes (MBP+, red) in cultures of aNSCs undergoing differentiation in the absence or presence of CXCL12
(10 ng/ml). e Quantitative analysis of maturing neurons (βΙΙΙ-tubulin+). f Quantitative analysis of mature oligodendrocytes (MBP+). g Representative
images of immunofluorescent staining (upper panel) for NPCs (DCX+, red) and OPCs (NG2+, green) and (lower panel) for maturing neurons (βΙΙΙ-tubulin+,
green) or oligodendrocytes (MBP+, red) in cultures of aNSCs undergoing differentiation in the absence or presence of the CXCR4 antagonist, AMD3100
(100 ng/ml, added twice a day), CXCL12 (10 ng/ml) alone, or CXCL12 and AMD3100 combined after 5 days in culture. Cultures with AMD3100 alone or
with no additive served as respective controls. h Quantitative analysis of neural progenitors NPCs (DCX+) and OPCs (NG2+). i Quantitative
analysis of maturing neurons (βΙΙΙ-tubulin+) or oligodendrocytes (MBP+). Results in b, c, e, f, h, and i are presented as percentages of
nuclei numbers and represent the mean ± SEM from three independent experiments. Nuclei were visualized by DAPI counterstaining.
*p ≤ 0.05; **p = 0.02; ‡p ≤ 0.002; § p = 0.04. Scale bars: a, d, g 50 μm
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Our immunohistochemistry analysis suggested that
NPCs and OPCs that co-express CXCL12 could also be
the source of the CXCL12 that was detected at the DG
and CC of EAE-recovered mice. The expression of
CXCL12 by neuronal progenitors or mature neurons has
been reported [33, 38, 47]. In contrast, the expression of
CXCL12 by OPCs or by oligodendrocytes had not been
described before either during development or in the
adult CNS, despite intensive studies on the involvement
of CXCL12 in the proliferation [9, 27, 39], differenti-
ation, and maturation of OPCs [8, 27] and their CNS
migration [27, 39]. We have, therefore, confirmed that
NG2+ OPCs in the CC and the spinal cord of EAE-
recovered mice do express CXCL12, using confocal
Fig. 8 NPCs and OPCs differentiated in vitro co-express CXCR4 and its CXCL12 ligand. a, b Representative immunofluorescent images of a NPCs
(DCX+, green) or b OPC (NG2+, green) co-labeled for CXCL12 (red) and CXCR4 (blue). Cells were differentiated from aNSCs cultured in differentiation
medium for 6 days. Nuclei were visualized by DAPI counterstaining (white). Scale bar: 20 μm. The panels at the right show individual channels for NPCs
or OPC co-stained for CXCR4 (blue) and CXCL12 (red). Scale bar: 20 μm
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three-dimensional reconstruction and colocalization
analyses. A similar confocal microscopy analyses con-
firmed that also in vitro differentiating NG2+ OPCs co-
express CXCL12, independent of inflammatory factors
present in the CNS during active EAE, suggesting a vital
function for a basal expression of CXCL12 by OPCs.
Numerous studies have reported the expression of the
CXCR4 and CXCR7 receptors by NSCs, OPCs, and NPCs,
and the functional responses to activation by their only
ligand, CXCL12, during development [48] and in inflamed
adult CNS, particularly in MS/EAE [7, 8, 11, 22, 49].
While our detection of CXCR4 expression by NG2+ OPCs
and DCX+ NPCs in CC and DG, respectively, of EAE-
recovered mice was not surprising in view of these studies
and of similar observations for in vitro differentiated
NPCs and OPCs [8, 11, 27, 36, 39] (and Figs. 8 and 9),
the finding that a significant proportion of these CXCR4+
DCX+ NPCs and CXCR4+ NG2+ OPCs co-expressed also
the CXCR4 ligand, CXCL12, was quite unexpected. Most
importantly, the frequencies of CXCL12+ CXCR4+ DCX
+ NPCs and CXCL12+ CXCR4+ NG2+ OPCs in the DG
and CC not only increased during disease progression
but also during recovery with numbers significantly
greater by about 1.5-fold than those at disease peak.
These findings further support potential involvement of
CXCL12 in promoting endogenous neuro/oligodendro-
genesis and the differentiation/maturation of NPCs and
OPCs towards myelin and neuronal repair following
EAE-associated CNS tissue damage.
NG2+ OPCs and DCX+ NPCs that co-express CXCR4,
and its ligand, CXCL12, have not been previously reported
in EAE models or in patients with MS. Whether such
CXCL12+ CXCR4+ neural progenitor cells can be intrin-
sically activated to differentiate via autocrine signaling
mechanisms in MS/EAE has not been determined. Pub-
lished data, however, suggest that CXCL12 can act as an
Fig. 9 The proportion of neural progenitor cells co-expressing CXCR4 and CXCL12 is elevated with the onset and progression of clinical EAE and
further increased following clinical recovery. a Representative immunofluorescent image of NPC in the DG of EAE-recovered mouse co-labeled for
DCX (green), CXCR4 (blue), and CXCL12 (red). Cell marked with dashed line is shown in higher magnification in the panel on the right in individual
channels and merged image. b Quantitative analysis of the percentage of NPCs (DCX+) that co-express CXCR4 and CXCL12 (DCX+ CXCR4+ CXCL12+)
out of DCX+ CXCR4+ NPCs in the DG of mice with indicated EAE clinical episode or following spontaneous recovery. *p = 0.01 and **p < 4 × 10−5
compared to naïve; ***p = 0.004; #p = 6.5 × 10−5. c Immunofluorescent image of OPC in the CC of EAE-recovered mice co-labeled for NG2 (green),
CXCR4 (blue), and CXCL12 (red). Cell marked with dashed line is shown in higher magnification in the panel on the right in individual channels and
merged image. d Quantitative analysis of the percentage of OPCs co-expressing CXCR4 and CXCL12 (NG2+ CXCR4+ CXCL12+) out of NG2+ CXCR4+ OPCs
in the CC of mice with indicated EAE clinical episode or following spontaneous recovery. Percentages were determined in five consecutive
sections from each mouse (n = 3). Data are mean ± SEM from two independent experiments. *p = 0.01, **p = 0.003, and ***p = 0.0002 compared
to naïve; #p = 0.04 (one tail t test); §p = 0.004. Nuclei were visualized by DAPI counterstaining (white). Scale bar: a, c 10 μm; bar in right images 5 μm
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autocrine modulator of neuronal activity [40, 47, 50].
Thus, it is plausible that the elevated numbers of CXCL12+
CXCR4+ DCX+ NPCs and of CXCL12+ CXCR4+ NG2+
OPCs that persist in the CNS of EAE-recovered mice are
intrinsically activated via autocrine signaling mechanisms
to differentiate into neural cells that would eventually
mediate the repair of inflammation-associated myelin/
neuronal damage. Such a self-sufficient mechanism (auto-
crine signaling) of NPCs and OPCs activation is likely to
be essential for continuing the repair of the myelin/neural
damage after the deleterious inflammation has subsided,
and with it, the CXCL12 secreted by the inflammatory
cells, particularly, when the small amounts of CXCL12
secreted by the vascular endothelia cells may not be suffi-
cient for the intensive myelin/neuronal repair required
after the deleterious inflammation.
We first detected an increase in the number of NPCs
and OPCs at early clinical onset, during early inflamma-
tory phase when the number of GFAP+ CXCL12+ astro-
cytes and the level CXCL12 also increase in the CNS
([2–4, 35], and this study). This suggests that the
CXCL12, a major inflammatory cell chemoattractant
[11], both facilitates inflammatory damage to CNS tissue
during disease progression and promotes proliferation of
NPCs and OPCs via paracrine signaling mechanisms,
as many of the NPCs and OPCs express the CXCL12
receptor, CXCR4 [7, 8, 11, 27, 36]. The significant in-
crease in neural progenitors during early EAE onset
suggests that the endogenous neural repair mecha-
nisms are being activated and built up already with
development of the inflammation in CNS, and that
the CXCR4-dependent activation by CXCL12 secreted by
inflammatory cells may further drive the NPCs and OPCs
towards differentiation/maturation and remyelination and
neuronal repair [8, 10, 16]. Apparently, such myelin/
neuronal protection/repair mechanisms are not sufficient
to compete with the CNS damage incurred by inflamma-
tion. However, the endogenous repair process becomes
more effective during the recovery phase when the CNS
inflammation/damage is arrested and the CXCL12-
expressing neural progenitors can increase in numbers
and differentiate to mature neurons and oligodendrocytes
without being perturbed by the deleterious inflammation.
The studies by McCandless et al. [4] and Meiron et al.
[51] support the role of CXCL12 in neural protection
following CNS inflammation in EAE. They showed in
C57BL/6 mice that blocking CXCR4 activation by ad-
ministering the CXCR4 antagonist, AMD3100 [4], or
by anti-CXCL12 antibody [51] significantly increases
the clinical severity of EAE induced by myelin oligo-
dendrocyte glycoprotein which, unlike untreated mice,
reach a plateau phase without significant remission.
Different mechanisms were suggested in theses stud-
ies: aggravation of disease in the AMD3100-treated
mice was attributed to elevated CNS inflammation as-
sociated with the disruption of CXCR4’s function in
limiting the infiltration of autoreactive effector cells
and migration of leukocytes into the parenchyma [4].
The disease aggravation by anti-CXCL12 antibodies
was attributed to the role of CXCL12 in redirecting
the polarization of effector Th1 cells into antigen-specific
regulatory T cells in a CXCR4-dependent manner. How-
ever, the increase in the number of CXCR4+ NPCs and
OPCs and of CXCL12 expressing CXCR4+ NPCs/OPCs
already at early disease onset (shown above) suggests that
the blockade of the CXCR4-dependent endogenous po-
tential for neural protection/repair of CXCR4-expressing
NPCs and OPCs through paracrine or autocrine CXCL12/
CXCR4 signaling mechanisms may also be at play in dis-
ease aggravation and lack of remission following treatment
with these agents. Therefore, it is likely that blocking the
CXCR4-dependent promotion of NPC and OPC prolifera-
tion at an early phase of the disease can also contribute to
aggravation of the disease by perturbing the remission
mechanisms (myelin/neuronal protection) following treat-
ment with AMD3100 or with anti-CXCL12 antibodies.
Conclusions
This study highlights the post-inflammatory beneficial
role of CXCL12 in adult CNS following MS-like inflam-
matory damage. In mice with EAE, the CXCL12/CXCR4
axis appears to be involved in promoting the endogen-
ous myelin and neuronal repair capacity, particularly in
mice undergoing spontaneous recovery. The spontan-
eous recovery from severe clinical EAE was associated
with elevated CXCL12 expression in the DG and CC of
spontaneously recovered mice, even though the CNS
inflammation has subsided. The data presented above
link CXCL12 expression in the DG and CC of EAE-
recovering mice to promotion of the endogenous neuro/
oligodendrogenesis. A significant proportion of the newly
generated progenitor cells are CXCR4+ CXCL12+ NPCs
and OPCs, endowed with intrinsic potential of neuro/
oligodendroglial differentiation and myelin/neuronal re-
pair via autocrine signaling mechanisms. The detection of
CXCL12+ CXCR4+ DCX+ NPCs and CXCL12+ CXCR4+
NG2+ OPCs in the DG and CC, respectively, of mice with
EAE and their significant increase in numbers in
spontaneously recovered mice are consistent with a post-
CNS-inflammation role of CXCL12 in promoting the
endogenous potential of repairing myelin and neuronal
damage, likely via self-sufficient (autocrine) signaling
mechanism which is not dependent on CXCL12 secreted
during inflammation.
Notably, the detection at the DG and CC of naïve
mice of relatively small, but consistent, numbers of
CXCL12+ CXCR4+ NPCs and CXCL12+ CXCR4+
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OPCs, respectively, may also link the CXCL12/CXCR4
axis to the maintenance of neural homeostasis in normal
adult CNS through autocrine signaling mechanisms. This
intriguing possibility warrants further investigation.
Additional files
Additional file 1: Figure S1. High expression of CXCL12 in the CNS of
mice with chronic clinical EAE. (a, b) Immunofluorescent images of spinal
cord tissue sections (L1–L6) from mice with ongoing EAE (day 50 after
immunization; clinical score =3) and from naive mice (a) immunostained
for CXCL12 (red) or (b) co-stained for CXCL12 (green) and GFAP (red).
(c) Immunofluorescent image of the cortex of the mice in panel a
immunostained for CXCL12 (red). In a and c, nuclei were counterstained
with DAPI (blue). Scale bars: a and c, 100 μm; b, 20 μm. (TIF 8873 kb)
Additional file 2: Figure S2. The CXCL12 expression, CXCL12+ NPCs
and CXCL12+ OPCs in the DG and CC of mice that did not recover from
EAE, compared to recovered mice or mice at the peak of the disease.
Brain sections of mice that did not recover from EAE (non-recovered;
clinical score 2) were taken at the end point of the experiment (day 65
post-immunization which is also close to the time points after
immunization when EAE-recovered mice were taken for analysis; Fig. 1a).
The sections were immmunostained for MAC2 (green) or CXCL12 (red),
or for co-immunostained for CXCL12 and immune markers of astrocytes
(GFAP), NPCs (DCX), or OPCs (NG2). The representative images from the
immunostained sections from the non-recovered mice (n = 4) were
placed for comparison side by side with the images from recovered mice,
mice at the peak of the disease, and from naïve mice, which are presented
in Fig. 2. Representative images show (a) immunostaining for MAC2 (green)
in brain sections from the D3V. (b) Immunostaining for CXCL12 (red)
in brain sections from CC (central/caudal regions, denoted by dashed
lines). (c) Immunostaining for CXCL12 (red) in brain sections from the
DG. (d) Co-immunostaining for GFAP (green) and CXCL12 (red) in
brain sections from the DG. (e) Co-immunostaining for NPCs (DCX+,
green) and CXCL12 (red) in the DG. (f) Co-immunostaining for OPCS
(NG2+, green) and CXL12 (red) in CC. Nuclei were visualized by DAPI
counterstaining (blue). The brain sections were from same immunizations.
The images shown for the non-recovered mice were from immunostaining
of preserved free-floating brain sections that were kept in the presence of
NaN3 for 18 months. Scale bar: a–f, 50 μm. Arrowheads in f indicate OPCs
(NG2+) co-expressing CXCL12. (TIF 9358 kb)
Additional file 3: Figure S3. In vitro differentiation of aNSCs isolated
from the subventricular zone of adult mice. Neurospheres that were
expanded in neurosphere medium in the presence of growth factors
were differentiated on PDL-coated coverslips in the presence of 5 % FCS
in the absence of growth factors. On day 0, a very small proportion of
cells in neurospheres were NPCs (DCX+), but none were OPCs (NG2+),
maturing neuronal cells (NF200+), or oligodendrocytes (MBP+). The
differentiation cultures were fixed after 2, 4, and 8 days and immunostained
for indicated markers of neuronal, oligodendroglial, or astrocytic lineages. At
day 2 of culture, differentiation to NPCs (DCX+), OPCs (NG2+), and astrocytes
(GFAP+) were observed, which matured with time (day 4 and 8) to neuronal
cells (β-tubulin III+), MBP-producing oligodendrocytes, or to astrocytes.
Nuclei were visualized by DAPI counterstaining. Scale bar: 50 μm.
(TIF 8316 kb)
Additional file 4: Figure S4. CXCL12 promotes differentiation and
maturation of aNSCs dose response. The data are from immunofluorescent
staining for NPCs (DCX+, red) and OPCs (NG2+, green) (as in Fig. 7a) and for
maturing neurons (βΙΙΙ-tubulin+, green) or oligodendrocytes (MBP+, red) (as
in Fig.7d) of cultures of aNSCs undergoing differentiation in the absence or
presence of CXCL12 (5, 10, or 20 ng/ml). The representative images for the
effect of 10 ng/ml CXCL12, as an optimal dose, is shown in Fig. 7. The effects
of the different concentration of CXCL12 on the in vitro differentiation and
maturation of aNSCs are summarized here quantitatively. (a) Quantitative
analysis of NPCs (DCX+). (b) Quantitative analysis of OPCs (NG2+). (c)
Quantitative analysis of maturing neurons (βΙΙΙ-tubulin+). (d) Quantitative
analysis of mature oligodendrocytes (MBP+). The effect of 5 ng/ml CXCL12
was lower than other concentrations; effects of 10 and 20 ng/ml CXCL12
were quite comparable, with 10 ng/ml being somewhat more optimal. We
therefore showed in the body of the manuscript (Fig. 7) only the effects of
CXCL12 at 10 ng/ml concentration. Results in a–d are presented as
percentages of nuclei numbers and represent the mean ± SEM from
three independent experiments. *p ≤ 0.05; **p < 0.01. (TIF 8921 kb)
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